European Journal of Cardio-Thoracic Surgery · 2015 · 53 citations · 20 references
MedicineOncologyPathologyMetastasisNeoplasiaThoracic OncologyCancer StagingCancer Survival AnalysisLung CancerMalignant NeoplasmsMalignant TumorsTumor ClassificationDisease-free Survival AnalysisDisease-free Survival AssessmentLung AdenocarcinomaLung Cancer StagingLymphatic Vessel InvasionMicropapillary PatternPrognostic Factors AnalysisPrognostic Variables
OBJECTIVES: There is uncertainty as to which factors determine the aggressiveness of lung adenocarcinoma with a micropapillary pattern (MPP). The present study aimed to clarify the influence of a MPP on the malignant aggressiveness of clinical stage IA lung adenocarcinoma. METHODS: We retrospectively examined 347 consecutive patients with clinical stage IA lung adenocarcinoma who underwent complete resection. We defined MPP-positive as accounting for ≥5% of the entire tumour. RESULTS: Forty-eight (14%) and 299 (86%) patients were MPP-positive and negative, respectively. Lymphatic (P = 0.003) and vessel (P = 0.029) invasion as well as lymph node metastasis (P = 0.002) were more frequent in the MPP-positive than negative group. Five-year disease-free survival (DFS) rates were significantly lower in the MPP-positive than negative group (69.7 vs 89.3%, P < 0.001). Multivariate analysis for DFS showed that MPP (P = 0.048), lymphatic invasion (P = 0.003) and vessel invasion (P = 0.002) were independent poor prognostic factors. In addition, higher proportions (<5%, 5-30% and ≥30%) of MPP were associated with a poorer prognosis (89.3, 76.0, and 48.1%, respectively; P < 0.001). The prognosis of patients with MPP-positive tumours and negative tumours harbouring lepidic and solid predominant growth patents did not differ (100 vs 96.8%, P = 0.564; 66.7 vs 62.5%, P = 0.791, respectively). On the other hand, the prognosis tended to be poorer for patients with papillary predominant MPP-positive tumours than for those with negative tumours (62.5 vs 82.5%, P = 0.075). CONCLUSIONS: MPP has an effect on tumour malignancy and patients with tumours harbouring a higher ratio of MPP or papillary predominant subtypes have worse survival.
20
Peter Goldstraw, John Crowley, Kari Chansky et al. · Journal of Thoracic Oncology · 2007 · 3.7K citations
Noriko Motoi, János Szőke, Gregory J. Riely et al. · The American Journal of Surgical Pathology · 2008 · 373 citations
Micropapillary Component in Lung Adenocarcinoma
Mitual Amin, Pheroze Tamboli, Shakil H. Merchant et al. · The American Journal of Surgical Pathology · 2002 · 330 citations